HOME >> BIOLOGY >> NEWS
Other highlights in the August 4 JNCI

Low Levels of "Good" Cholesterol Associated With Increased Postmenopausal Breast Cancer Risk

Low levels of high-density lipoprotein (HDL) cholesterol--the "good" cholesterol--are associated with an increased risk of postmenopausal breast cancer in overweight and obese women, according to a new study.

Low HDL cholesterol is a component of metabolic syndrome, which is also characterized by obesity, glucose intolerance, and hypertension. Both metabolic syndrome and breast cancer have been increasing worldwide. Increased levels of insulin and insulin-like growth factor in metabolic syndrome have been linked to breast cancer, but the role of other biomarkers, such as HDL cholesterol is not known.

Anne-Sofie Furberg, M.D., Ph.D., of the University of Troms in Norway, and colleagues analyzed data from a Norwegian cohort of nearly 39,000 women over a follow-up period of 21 years. Low levels of HDL cholesterol were associated with an increased risk of postmenopausal breast cancer in women who were overweight or obese. The association was strongest in women who gained weight over the years of follow-up.

Contacts:

  • Anne-Sofie Furberg, Institute of Community Medicine, University of Troms, 47-99-41-4007, anne-sofie.furberg@ism.uit.no
  • Inger Thune, Institute of Community Medicine, 47 91 37 27 17, inger.thune@ism.uit.no

    HER-2/neu Overexpression in Breast Cancer Does Not Adversely Influence Response to First-Line Chemotherapy

    Breast cancer patients with tumors that overexpress the gene HER-2/neu are more likely to have a poor clinical outcome. A new study finds that HER-2/neu overexpression does not lead to a poorer response to chemotherapy in women with metastatic breast cancer.

    There is some evidence that HER-2/neu overexpression is associated with a better response to anthracycline-based chemotherapy, b
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    3-Aug-2004


    Page: 1 2 3

    Related biology news :

    1. Other highlights in the September 1 JNCI
    2. Other highlights in the August 18 JNCI
    3. Other highlights in the July 7 JNCI
    4. Other highlights in the June 16 JNCI
    5. Other Highlights in the June 2 JNCI
    6. Other highlights in the May 19 JNCI
    7. Other highlights in the May 5 JNCI
    8. Other highlights of the March 17 issue of JNCI
    9. Other highlights in the March 3 issue of JNCI
    10. Other highlights in the February 18 issue of JNCI
    11. Other highlights in the February 4 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:7/23/2019)... ... , ... NanoFUSE is pleased to announce the ... spine and orthopedic use. Bioactive glass is a calcium phosphate coated silica that ... orthopedics for over 30 years and now NanoFUSE Biologics has used advanced research ...
    (Date:7/19/2019)... ... July 19, 2019 , ... ... and Crystalline States – Insights from Synchrotron X-ray Pair Distribution (SXPDF) Studies”. The ... with Chris Benmore of Argonne National Laboratory and Gabriel de Araujo of the ...
    (Date:7/17/2019)... Pa. (PRWEB) , ... July 15, 2019 , ... ... of computational science expertise exclusively for Life Sciences and Healthcare companies, announces the ... provide critical advisory services and strategic direction to start-up and emerging bio-pharma companies ...
    Breaking Biology News(10 mins):
    (Date:6/11/2019)... Fla. (PRWEB) , ... June 10, 2019 , ... ... in science and technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check ... the Eppendorf Group) and will educate viewers about how its technology facilitates laboratories ...
    (Date:6/11/2019)... POWAY, Calif. (PRWEB) , ... June 11, 2019 ... ... parent company of Personalized Stem Cells Inc. (PSC) , has announced that ... of Public Health, Food and Drug Branch for manufacturing. This is an ...
    (Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms of cancer ... breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor ... T cell receptors known as “CARs”. The CAR enables the final product to produce ...
    (Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
    Breaking Biology Technology:
    Cached News: